k.farrugia
TL3 Regular · Thessaloniki, GR
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 31 December 2024 · last posted 2d · groups: journal-club
142Posts here
4Topics
0Solutions
1.9kLikes received
3.2kLikes given
33Badges
372Days visited
9kPosts read
Recent activity
Full stream-
CJC-1295 with and without DAC: what the modification does Replied, post #123 · Compounds › Secretagogues & GH axis · 26 Jul 2026 · 22 likes I read post #121 twice before replying, because I had assumed the opposite. Why this subcategory is stricter about sourcing than most: the evidence base is weaker and…
-
Priming a pen and whether the primed volume is wasted Replied, post #22 · Devices › Pens & autoinjectors · 24 Jul 2026 · 1 like I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #74 · Start Here › Welcome · 23 Jul 2026 · 1 like The compound and evidence pages are updated regularly and they are worth reading when you are new. They answer the meta questions like "do we have data on this" and…
-
Semaglutide formulation: what is in the licensed product besides the peptide Replied, post #33 · Compounds › Semaglutide · 20 Jul 2026 · 1 like This follows post #30 rather than contradicting it. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still…
-
Seven-day rolling means and why weekly readings mislead Replied, post #42 · Outcomes › Progress reports · 16 Jul 2026 · 0 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
How shortages have affected compounding permissions Replied, post #42 · Access › Shortages · 16 Jul 2026 · 1 like Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on when they stopped. Gaps of months might require retitration…
-
Pancreatitis history and the risk calculus Replied, post #29 · Safety › Contraindications · 16 Jul 2026 · 10 likes Picking up post #26: that is the part I would want checked first. Pregnancy: these compounds are not approved for pregnancy. The potential risks outweigh potential…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #71 · Analytics › Home & field testing · 10 Jul 2026 · 0 likes Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes…
-
Historical amylin analogues and what happened to them Replied, post #29 · Compounds › Cagrilintide & amylin analogues · 9 Jul 2026 · 8 likes Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that…
-
A site rotation scheme that is easy enough to actually follow Replied, post #109 · Practice › Administration · 8 Jul 2026 · 2 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #22 · Practice › Dosing & titration · 28 Jun 2026 · 0 likes The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The…
-
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Replied, post #31 · Compounds › Secretagogues & GH axis · 26 Jun 2026 · 1 like Coming back to post #29, because the follow-up matters more than the original answer. Practical note that does not fit anywhere else. Whatever you conclude from this…